Handbook of HER2-targeted agents in breast cancer

Alvarez, Ricardo H; Cortés, Javier; Mattos-Arruda, Leticia; Falzon, Mary; Fasolo, Angelica; Gandy, Michael; Gianni, Luca; Harbeck, Nadia; Piccart, Martine; Zambelli, Stefania; Zardavas, Dimitrios

​Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year.  Of these cases, approximately  15–25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes.  However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer  provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.

Details

Published by: Springer Healthcare

Publication Date: 2014-11-03

Format: Paperback

ISBN-13: 9781907673931

DOI: 10.1007/978-1-907673-94-8

Dimensions: 201cm x127cm

Pages: 96